A bit more detail from Bell Potter's analyst re the Adult aGvHD trial:The trial will be substantially funded by a collaboration with the Blood and Marrow Transplant Clinical Trial Network – being a body funded by the National Institute of Health in the US. There are at least 35 hospitals involved in the trial which is currently in planning and is expected to commence recruitment in the new year. Participants in the trial will have failed on Jakafi (ruxolitinib) therapy and as there are no other treatment options, this will be a single arm trial in approximately 70 patients. The Activity Report does not discuss the planned clinical trial in chronic lower back pain. We expect the priorities for the company are the activities which will see it begin to generate revenues in the shortest possible time frame.
Aloha.
Cell Therapy News/Articles, page-17155
-
- There are more pages in this discussion • 1,237 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.010(0.69%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.49 | $1.44 | $3.472M | 2.379M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12398 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 5440 | 3 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |